DV
Dividend Vision

VIVS — VivoSim Labs, Inc.

VivoSim Labs, Inc. (VIVS)

Total return is -99.9% over the past 14.5 years, 739.1 points behind SPY at 639.2%. Its deepest 1-year drawdown was 93.1%.

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company that develops and provides testing services using three-dimensional human tissue models of liver and intestine to evaluate drug toxicology, mechanism of action, and side effect profiles for pharmaceutical and biotech companies during drug development. The company does not currently distribute to shareholders. VivoSim Labs operates as an operating company without fund characteristics and is appropriate for investors focused on biotechnology services rather than current income.

VIVS key facts

Asset type
Stock
Asset class
Equity
Inception date
02/14/2012
Last close
$0.32
Market cap
$1,764,156
Average volume
1465000.0
Payment date
08/19/2020
Beta
1.4
Payout ratio
0.0
P/E ratio
0.75
Forward P/E
0.0
EPS
$-4.67